A Phase I Trial of Weekly Nab-paclitaxel Plus Carboplatin With Thoracic Radiotherapy for Non-small Cell Lung Cancer

• Published in: In vivo (Athens) 2024-01, Vol.38 (1), p.259-263
• Main Authors: Kubota, Tetsuya, Sakai, Mizu, Anabuki, Kazuki, Takamatsu, Kazufumi, Mukaida, Kenichi, Kobayashi, Kana, Yamagami, Takuji, Yokoyama, Akihito
• Format: Article
• Language: English
• Subjects: Antineoplastic Combined Chemotherapy Protocols - adverse effects; Carboplatin; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - radiotherapy; Humans; Lung Neoplasms - drug therapy; Lung Neoplasms - radiotherapy; Paclitaxel
• ISSN: 0258-851X; 1791-7549
• DOI: 10.21873/invivo.13433

This study aimed to evaluate the safety and recommended dose of nab-paclitaxel in combination with carboplatin and thoracic radiotherapy for locally advanced non-small cell lung cancer (NSCLC). Nab-paclitaxel was administered weekly with escalating doses, combined with carboplatin area under the curve (AUC) 2 and concurrent standard thoracic radiotherapy. Escalating doses of nab-paclitaxel were as follows: level 0, 30 mg/m ; level 1, 35 mg/m ; level 2, 40 mg/m ; level 3, 45 mg/m Results: Twelve patients were enrolled and received the treatment according to the protocol; seven patients (58%) had squamous cell carcinoma and all cases had stage III disease. At level 1, none of the three patients experienced dose limiting toxicity (DLT). At level 2, one of the first three patients experienced a fatal DLT of bronchopulmonary hemorrhage. None of the three more additional patients experienced DLT. At level 3, two of the three patients experienced a DLT of grade 3 febrile neutropenia and grade 4 neutropenia, respectively. Consolidation chemotherapy was provided to 10 of 12 patients. Radiation pneumonitis developed in five of 12 patients (42%). Eight patients (66.7%) showed partial response, and four (33.3%) showed stable disease. For the above reasons, level 2 (40 mg/m ) was considered the recommended dose in this study. Concurrent chemoradiotherapy with weekly nab-paclitaxel (40 mg/m ) and carboplatin (AUC 2) is a feasible and well-tolerated regimen in patients with previously untreated locally advanced NSCLC. A phase II trial with this regimen is warranted.